安络化纤丸联合阿德福韦酯治疗慢性乙型肝炎肝纤维化

目的研究安络化纤丸联合阿德福韦酯治疗慢性乙型肝炎肝纤维化的临床疗效。方法60例慢性乙型肝炎患者随机分为A、B两组，A组采用安络化纤丸联合阿德福韦酯治疗，B组单独采用阿德福韦酯治疗，疗程均为半年。观察治疗前、治疗6个月后的血清HA、LN、PCIII、IV—C水平和肝功能指标（TBIL、AIJT、AST、ALB）及HBV—DNA定量。结果A、B两组血清HA、LN、PCIII、IV—C、TBIL、ALT、AST均随治疗时间逐渐降低，除PCIII外（P〉0．05），其余三项指标治疗后两组差异有统计学意义（P〈0．05）。两组治疗后，肝功能指标均较治疗前改善，但A组改善较B组更为明显，差异有统计学意义（P〈0．05）。在HBV—DNA定量方面，两组治疗后均较治疗前下降，均有统计学意义（P〈0．05），但两组对比差异无统计学意义（P〉0．05）。结论安络化纤丸联合阿德福韦酯对慢性乙型肝炎肝纤维化有良好的抗纤维化效果，并能改善生化指标，疗效优于单独使用阿德福韦酯组。

Combined Anluohuaxianwan and Adefovir Dipivoxil Treatment on Patients with Hepatic Fibrosis of Chronic Hepatitis B

Objective To study the clinical effect of combined anluohuaxianwan and adefovir dipivoxil treatment on patients with chronic hepatitis B. Methods 60 patients with chronic hepatitis B were randomly divided into 2 groups,namely group A and group B.Group A received a combined treatment with anluohuaxianwan and adefovir dipivoxil, while group B received adefovir dipivoxil only. The therapeutic period was 6 months. The levels of HA, LN, PCIII, IV-C ,TBIL, ALT, AST, and HBV-DNA quantity were determined both before and after the treatment. Results After 6 months of treatment, the levels of HA, LN, PCⅢ and IV-C were lower in both group A and B. The improvement of HA, LN and IV-C in group A was significantly better than those in group B （P〈0.05）. The levels of TBIL, ALT and AST were improved in both group A and B after the treatment, and the improvement of TBIL, ALT and AST in group A was significantly better than group B（P〈0.05）. However,the level of HBV-DNA was lower in both group A and B after the treatment, and the difference in improvement between the group A and B was not significant （P 〉0.05 ）. Conclusion Combination of anluohuaxianwan and adefovir dipivoxil is effective in the treatment of patients with hepatic fibrosis of chronic hepatitis B.